| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory for Molecular Brain Research [M. T., R. M., Y. Sh.] and Departments of Neurosurgery [Y. Sa.] and Radiology [R. O., H. S.], Hokkaido University School of Medicine, Sapporo 060 Japan, and Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), 1066 Epalinges, Switzerland [R. D. I.]
Recent studies suggest that a balance may exist between the cell cycle arrest and apoptosis-inducing functions of the p53 tumor suppressor gene. Adenoviral p21 transduction attenuates apoptosis, whereas deletion of the p21 gene promotes it, and p21-null xenografts respond better than isogenic p21-wild type tumors to irradiation. Hence, the role of p53 in dictating the clinical response to radiotherapy and chemotherapy may be more complex than previously thought. We have analyzed survival and radiation response (regrowth-free period) of 42 patients with glioblastomas whose p53 status was determined by a sensitive yeast functional assay. Multivariate analysis revealed that p53 mutation is associated with longer survival (P < 0.02). Among 36 radiation-treated patients, the regrowth-free period after treatment was significantly longer for tumors with p53 mutations (P < 0.0001), and p53 mutation was the sole independent factor predictive of radiotherapeutic response (P < 0.01). Survival time after regrowth was independent of p53 status, suggesting that the difference in survival was related to the treatment rather than to the intrinsic aggressiveness of the tumor. Thus, in this Northern Japanese population, p53 mutation is a marker for better radiation response in glioblastomas, and this results in significantly longer survival.
1 To whom requests for reprints should be addressed, at Laboratory for Molecular Brain Research, Department of Neurosurgery, Hokkaido University School of Medicine, North-15 West-7, Kita-Ku, Sapporo 060, Japan. Phone: 81-11-716-1161; Fax: 81-11-706-7878; E-mail: m_tada@med.hokudai.ac.jp.
Received 1/22/98. Accepted 3/17/98.
This article has been cited by other articles:
|
|
 |
|
  G. Afshar, N. Jelluma, X. Yang, D. Basila, N. D. Arvold, A. Karlsson, G. L. Yount, T. B. Dansen, E. Koller, and D. A. Haas-Kogan Radiation-Induced Caspase-8 Mediates p53-Independent Apoptosis in Glioma Cells. Cancer Res., April 15, 2006; 66(8): 4223 - 4232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Sarkaria, B. L. Carlson, M. A. Schroeder, P. Grogan, P. D. Brown, C. Giannini, K. V. Ballman, G. J. Kitange, A. Guha, A. Pandita, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2264 - 2271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol. Pathol., October 1, 2003; 56(5): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas Ann. Onc., July 1, 2002; 13(7): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. M. Dupertuis, M. Vazquez, J.-P. Mach, N. De Tribolet, C. Pichard, D. O. Slosman, and F. Buchegger Fluorodeoxyuridine Improves Imaging of Human Glioblastoma Xenografts with Radiolabeled Iododeoxyuridine Cancer Res., November 1, 2001; 61(21): 7971 - 7977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Simmons, K. R. Lamborn, M. Takahashi, P. Chen, M. A. Israel, M. S. Berger, T. Godfrey, J. Nigro, M. Prados, S. Chang, et al. Analysis of Complex Relationships between Age, p53, Epidermal Growth Factor Receptor, and Survival in Glioblastoma Patients Cancer Res., February 1, 2001; 61(3): 1122 - 1128. [Abstract] [Full Text]
|
|
|
|
|
|
M. Iwato, O. Tachibana, Y. Tohma, Y. Arakawa, H. Nitta, M. Hasegawa, J. Yamashita, and Y. Hayashi Alterations of the INK4a/ARF Locus in Human Intracranial Germ Cell Tumors Cancer Res., April 1, 2000; 60(8): 2113 - 2115. [Abstract] [Full Text]
|
|
|
|
|
|
M. Marutani, H. Tonoki, M. Tada, M. Takahashi, H. Kashiwazaki, Y. Hida, J.-i. Hamada, M. Asaka, and T. Moriuchi Dominant-Negative Mutations of the Tumor Suppressor p53 Relating to Early Onset of Glioblastoma Multiforme Cancer Res., October 1, 1999; 59(19): 4765 - 4769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Dahlberg, E. I. Azzam, Y. Yu, and J. B. Little Response of Human Tumor Cells of Varying Radiosensitivity and Radiocurability to Fractionated Irradiation Cancer Res., October 1, 1999; 59(20): 5365 - 5369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nozaki, M. Tada, H. Kobayashi, C.-L. Zhang, Y. Sawamura, H. Abe, N. Ishii, and E. G. Van Meir Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression Neuro-oncol, April 1, 1999; 1(2): 124 - 137. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Brown and B. G. Wouters Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents Cancer Res., April 1, 1999; 59(7): 1391 - 1399. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
